financetom
Business
financetom
/
Business
/
Analysis-Codelco boosts 2024 copper output but late push strains workers, delays maintenance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Analysis-Codelco boosts 2024 copper output but late push strains workers, delays maintenance
Jan 16, 2025 3:43 AM

SANTIAGO (Reuters) - Copper producer Codelco pushed hard at the end of last year to lift annual output slightly from a 25-year-low in 2023, but union workers and analysts said the tactics used were unsustainable as the company strives for annual production of 1.7 million metric tons by the end of the decade.

An internal document seen by Reuters showed Codelco's production reached 1.328 million tons in 2024, at the low end of its target range and just about 3,500 tons higher than the quarter-century low in 2023.

In its second-half push, workers interviewed said the world's largest copper producer shortened downtime, changed shift schedules and intensified production targets while delaying some needed maintenance until 2025. Analysts wondered how deeply Codelco tapped its reserves to make its numbers, and said new mines or sources of copper are needed to compensate for degradation of minerals at aging facilities.

An equipment operator at one of Codelco's largest mines, Chuquicamata, said there was more pressure in the second half of 2024 to reduce routine stoppages and avoid incidents that could cause a stoppage.

The worker, who asked not to be identified because they were not authorized to talk about internal operations, said Codelco has yet to fix bottlenecks in transporting minerals in the mine. Last February, Codelco said it needed to stop ore transport at Chuquicamata to replace conveyor belts. That maintenance was expected this year.

Workers said maintenance was delayed at smelters in Chuquicamata and El Teniente. Codelco did not respond to requests for information about those maintenance issues.

Chairman Maximo Pacheco said Codelco produced 160,000 tons of copper in December, its biggest month since 2019. Miners typically dip into reserves to increase December production, yet analysts said Codelco may have tapped them more than usual.

"Although it is normal for production to increase in December, we believe this huge jump can be attributed to a very aggressive reduction in inventories," said Juan Carlos Guajardo, head of the consultancy firm Plusmining.

"Codelco will have to replenish these inventories at some point."

LONG-TERM ISSUES STILL PERSIST

"The real battle will continue to be the advancement of the larger projects like Chuquicamata Underground or El Teniente, because these are the projects that will get the company to the level of 1.7 million tons per year," Guajardo said.

These large mine overhaul projects have been plagued by delays, accidents and construction mistakes.

In its latest results, Codelco said two new phases of El Teniente will start later than expected. Andesita, which had been scheduled to begin extraction in October, will now start "in the coming months." It said Andes Norte, originally slated for December, will start extracting in the first quarter.

Cristian Cifuentes, an analyst at the Center for Copper Studies (CESCO), said that the Ministro Hales mine is still at reduced capacity and the ramp up of Chuquicamata Underground has been "slower than we all thought."

"You can see the difficulties when you add all these things together," Cifuentes said, adding he thinks production will increase, but not at the levels Codelco wants.

Company data indicated that much of Codelco's 2024 win could be attributed to its small Salvador mine coming online, which added 2,800 tons in October and November.

One analyst, who asked not to be named, said Codelco will show more output stemming from its purchase of 10% of Teck's Quebrada Blanca mine.

"I don't see how they will address (mineral) degradation except by entering new areas," the analyst said. "Every year Codelco invests between $4 and $4.5 billion and figures are still falling."

(Report by Fabian Andres Cambero; Editing by Alexander Villegas; Editing by David Gregorio)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Avadel Pharmaceuticals Receives Unsolicited Acquisition Proposal From Lundbeck
Avadel Pharmaceuticals Receives Unsolicited Acquisition Proposal From Lundbeck
Nov 14, 2025
09:12 AM EST, 11/14/2025 (MT Newswires) -- Avadel Pharmaceuticals ( AVDL ) said Friday that it received an unsolicited acquisition proposal from Lundbeck for up to $23 per share, which would reasonably be expected to result in a Company Superior Proposal under its existing agreement with Alkermes ( ALKS ) . The company previously agreed to be acquired by Alkermes...
Gladstone Investment to Redeem $74.8 Million in 2028 Notes
Gladstone Investment to Redeem $74.8 Million in 2028 Notes
Nov 14, 2025
09:12 AM EST, 11/14/2025 (MT Newswires) -- Gladstone Investment ( GAIN ) said Friday it will redeem on Dec. 16 all $74.8 million of its 8.00% notes due 2028. The company said noteholders will receive the full principal amount along with accrued and unpaid interest through the redemption date. The 2028 notes will be delisted from the Nasdaq Global Select...
First Solar to Build $330 Million South Carolina Plant
First Solar to Build $330 Million South Carolina Plant
Nov 14, 2025
09:13 AM EST, 11/14/2025 (MT Newswires) -- First Solar ( FSLR ) said Friday that it plans to build a new production facility in Gaffney, South Carolina, with an expected cost of $330 million. The company said the plant will handle final manufacturing steps for its Series 6 Plus modules, which begin production abroad, and is expected to add 3.7...
Forte Biosciences Q3 net loss per share improves
Forte Biosciences Q3 net loss per share improves
Nov 14, 2025
Overview * Forte Biosciences Q3 2025 net loss per share decreased compared to the same period in 2024 * Research and development expenses rose due to increased clinical trial activities * Company expects three clinical trial readouts for FB102 in 2026 Outlook * Forte expects three clinical trial readouts for FB102 in 2026 * Company anticipates topline data for celiac...
Copyright 2023-2026 - www.financetom.com All Rights Reserved